Evaluating the Safety and Efficacy of Humacyte Acellular Tissue-Engineered Vessel in a Real-World Combat Setting: A Retrospective Observational Multicenter Study
ATEV functioned as intended in the treatment of acute and combat-related vascular injuries. Conduit infection rate and amputations of the treated limbs were zero. Patency rates were acceptable, and losses of patency did not lead to loss of the treated limb. This study characterizes the first of its kind, cell-derived biologic engineered artery for use in civilian and military personnel who are injured during combat.
Authors
- Oleksandr Sokolov (ORCID: https://orcid.org/0000-0003-4991-0366)
- Shamik Parikh (ORCID: https://orcid.org/0009-0001-2380-439X)
- V. О. Shaprynskyi (ORCID: https://orcid.org/0000-0002-1437-7410)
- Oleh Skupyy
- Yuliya Yurkova
- Serhii Yurets
- Oleksandr Stanko (ORCID: https://orcid.org/0009-0008-1045-3210)
- Laura E. Niklason (ORCID: https://orcid.org/0000-0002-5156-504X)
- Maria Fadri
Institutions
- Odesa I. I. Mechnikov National University (UA)
- Odessa College (US)
- State University of Information and Communication Technologies (UA)
- Vinnytsia National Technical University (UA)
- Humacyte (United States) (US)
- Dnipro University of Technology (UA)
- Dnipro State Medical University (UA)
Publication Details
- Journal
- Military Medicine
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1093/milmed/usaf160
- Citations
- 2
- Primary Topic
- Tissue Engineering and Regenerative Medicine
- Type
- article
- Field-Weighted Citation Impact
- 4.01